[HTML][HTML] Exploring a peptide nucleic acid-based antisense approach for CD5 targeting in chronic lymphocytic leukemia
We herein report an innovative antisense approach based on Peptide Nucleic Acids (PNAs)
to down-modulate CD5 expression levels in chronic lymphocytic leukemia (CLL). Using …
to down-modulate CD5 expression levels in chronic lymphocytic leukemia (CLL). Using …
Exploring a peptide nucleic acid-based antisense approach for CD5 targeting in chronic lymphocytic leukemia.
E Cesaro, AP Falanga, R Catapano, F Greco… - PLoS …, 2022 - search.ebscohost.com
We herein report an innovative antisense approach based on Peptide Nucleic Acids (PNAs)
to down-modulate CD5 expression levels in chronic lymphocytic leukemia (CLL). Using …
to down-modulate CD5 expression levels in chronic lymphocytic leukemia (CLL). Using …
Exploring a peptide nucleic acid-based antisense approach for CD5 targeting in chronic lymphocytic leukemia
E Cesaro, AP Falanga, R Catapano, F Greco… - PLoS …, 2022 - ui.adsabs.harvard.edu
We herein report an innovative antisense approach based on Peptide Nucleic Acids (PNAs)
to down-modulate CD5 expression levels in chronic lymphocytic leukemia (CLL). Using …
to down-modulate CD5 expression levels in chronic lymphocytic leukemia (CLL). Using …
[HTML][HTML] Exploring a peptide nucleic acid-based antisense approach for CD5 targeting in chronic lymphocytic leukemia
E Cesaro, AP Falanga, R Catapano, F Greco… - PLoS ONE, 2022 - ncbi.nlm.nih.gov
We herein report an innovative antisense approach based on Peptide Nucleic Acids (PNAs)
to down-modulate CD5 expression levels in chronic lymphocytic leukemia (CLL). Using …
to down-modulate CD5 expression levels in chronic lymphocytic leukemia (CLL). Using …
Exploring a peptide nucleic acid-based antisense approach for CD5 targeting in chronic lymphocytic leukemia
E Cesaro, AP Falanga, R Catapano, F Greco… - PLOS ONE, 2022 - iris.unina.it
We herein report an innovative antisense approach based on Peptide Nucleic Acids (PNAs)
to down-modulate CD5 expression levels in chronic lymphocytic leukemia (CLL). Using bio …
to down-modulate CD5 expression levels in chronic lymphocytic leukemia (CLL). Using bio …
Exploring a peptide nucleic acid-based antisense approach for CD5 targeting in chronic lymphocytic leukemia.
E Cesaro, AP Falanga, R Catapano, F Greco… - PLoS ONE, 2022 - go.gale.com
We herein report an innovative antisense approach based on Peptide Nucleic Acids (PNAs)
to down-modulate CD5 expression levels in chronic lymphocytic leukemia (CLL). Using …
to down-modulate CD5 expression levels in chronic lymphocytic leukemia (CLL). Using …
Exploring a peptide nucleic acid-based antisense approach for CD5 targeting in chronic lymphocytic leukemia.
E Cesaro, AP Falanga, R Catapano, F Greco… - Plos one, 2022 - europepmc.org
We herein report an innovative antisense approach based on Peptide Nucleic Acids (PNAs)
to down-modulate CD5 expression levels in chronic lymphocytic leukemia (CLL). Using …
to down-modulate CD5 expression levels in chronic lymphocytic leukemia (CLL). Using …
Exploring a peptide nucleic acid-based antisense approach for CD5 targeting in chronic lymphocytic leukemia
E Cesaro, AP Falanga, R Catapano, F Greco… - PloS …, 2022 - pubmed.ncbi.nlm.nih.gov
We herein report an innovative antisense approach based on Peptide Nucleic Acids (PNAs)
to down-modulate CD5 expression levels in chronic lymphocytic leukemia (CLL). Using …
to down-modulate CD5 expression levels in chronic lymphocytic leukemia (CLL). Using …
Exploring a peptide nucleic acid-based antisense approach for CD5 targeting in chronic lymphocytic leukemia.
E Cesaro, AP Falanga, R Catapano, F Greco… - Plos one, 2022 - europepmc.org
We herein report an innovative antisense approach based on Peptide Nucleic Acids (PNAs)
to down-modulate CD5 expression levels in chronic lymphocytic leukemia (CLL). Using …
to down-modulate CD5 expression levels in chronic lymphocytic leukemia (CLL). Using …